.: ORİJİNAL ARAŞTIRMA
Polikliniğe Başvuran Pediatrik Psöriyazis Hastalarının Epidemiyolojik ve Klinik Olarak Değerlendirilmesi: Tanımlayıcı Çalışma
Evaluation of Epidemiological and Clinical Characteristics of Pediatric Psoriasis Patients Presenting to the Outpatient Clinic: A Descriptive Study
Turkiye Klinikleri J Dermatol. 2025;35(1):1-7
doi: 10.5336/dermato.2024-104973
Makale Dili: TR
Tam Metin
ÖZET
Amaç: Bu çalışmanın amacı, psöriyazis (PsO) tanılı çocukların sosyodemografik ve klinik özelliklerini değerlendirmek ve bu özelliklerin hastalık şiddetiyle ilişkisini belirlemektir. Gereç ve Yöntemler: Bu çalışma retrospektif kesitsel bir araştırmadır. Dermatoloji polikliniğine 01 Temmuz 2022 ile 30 Haziran 2023 tarihleri arasında başvurmuş, 18 yaş altı PsO tanılı 30 hasta çalışmaya dâhil edilmiştir. Hastalık şiddeti Psöriyazis Alan Şiddet İndeksi (PAŞİ) ile değerlendirilmiş ve diğer özelliklerle ilişkisi analiz edilmiştir. Bulgular: Hastaların %53,3'ü (n=16) erkek, %46,7'si (n=14) kadın, yaş ortalaması ise 12,10±5,22 yıldı. Olguların %23,3'ünde (n=7) stres, %13,3'ünde (n=4) enfeksiyon, %13,3'ünde (n=4) travma, %46,7'sinde (n=14) aile öyküsü, %6,7'sinde (n=2) ilaç kullanımı tespit edildi. Hastaların %43,3'ünün (n=13) plak, %26,7'sinin (n=8) guttat, %16,7'sinin (n=5) eritrodermik, %10'unun (n=3) invers, %3,3'ünün (n=1) jeneralize püstüler PsO olduğu tespit edildi. PAŞİ skoru en düşük 2,3 en yüksek 32,3 olup, ortalama skor 13,60±7,91 idi. PsO'nun şiddeti olguların %70'inde yüksek iken, %20'sinde hafif, %10'unda orta düzeyde idi. Kadınların (p=0,008) ve risk faktörü olanların (p<0,001) PAŞİ skoru, erkeklere ve risk faktörü olmayanlara kıyasla istatistiksel olarak anlamlı düzeyde daha yüksekti. Risk faktörleri arasında enfeksiyon geçirenlerin (p=0,024) ve aile öyküsü olanların (p<0,001) PAŞİ skoru daha yüksekti. Çoklu doğrusal regresyon analizine göre kadın cinsiyet (p=0,005) ve aile öyküsü varlığı (p=0,033) diğer değişkenlerden bağımsız olarak PAŞİ skorunda artış ile ilişkili bulundu. Sonuç: Pediatrik PsO olgularında hastalığın şiddeti, kadın cinsiyet ve pozitif aile öyküsü olan bireylerde daha yüksek olma eğilimindedir. Bu özelliklere sahip olgularda daha yoğun tedavi ve takip, klinik pratikte hastalık şiddetini kontrol altına almada faydalı olabilir.
Anahtar Kelimeler: Demografik özellikler; pediatrik psöriyazis; klinik özellikler; hastalık şiddeti
Amaç: Bu çalışmanın amacı, psöriyazis (PsO) tanılı çocukların sosyodemografik ve klinik özelliklerini değerlendirmek ve bu özelliklerin hastalık şiddetiyle ilişkisini belirlemektir. Gereç ve Yöntemler: Bu çalışma retrospektif kesitsel bir araştırmadır. Dermatoloji polikliniğine 01 Temmuz 2022 ile 30 Haziran 2023 tarihleri arasında başvurmuş, 18 yaş altı PsO tanılı 30 hasta çalışmaya dâhil edilmiştir. Hastalık şiddeti Psöriyazis Alan Şiddet İndeksi (PAŞİ) ile değerlendirilmiş ve diğer özelliklerle ilişkisi analiz edilmiştir. Bulgular: Hastaların %53,3'ü (n=16) erkek, %46,7'si (n=14) kadın, yaş ortalaması ise 12,10±5,22 yıldı. Olguların %23,3'ünde (n=7) stres, %13,3'ünde (n=4) enfeksiyon, %13,3'ünde (n=4) travma, %46,7'sinde (n=14) aile öyküsü, %6,7'sinde (n=2) ilaç kullanımı tespit edildi. Hastaların %43,3'ünün (n=13) plak, %26,7'sinin (n=8) guttat, %16,7'sinin (n=5) eritrodermik, %10'unun (n=3) invers, %3,3'ünün (n=1) jeneralize püstüler PsO olduğu tespit edildi. PAŞİ skoru en düşük 2,3 en yüksek 32,3 olup, ortalama skor 13,60±7,91 idi. PsO'nun şiddeti olguların %70'inde yüksek iken, %20'sinde hafif, %10'unda orta düzeyde idi. Kadınların (p=0,008) ve risk faktörü olanların (p<0,001) PAŞİ skoru, erkeklere ve risk faktörü olmayanlara kıyasla istatistiksel olarak anlamlı düzeyde daha yüksekti. Risk faktörleri arasında enfeksiyon geçirenlerin (p=0,024) ve aile öyküsü olanların (p<0,001) PAŞİ skoru daha yüksekti. Çoklu doğrusal regresyon analizine göre kadın cinsiyet (p=0,005) ve aile öyküsü varlığı (p=0,033) diğer değişkenlerden bağımsız olarak PAŞİ skorunda artış ile ilişkili bulundu. Sonuç: Pediatrik PsO olgularında hastalığın şiddeti, kadın cinsiyet ve pozitif aile öyküsü olan bireylerde daha yüksek olma eğilimindedir. Bu özelliklere sahip olgularda daha yoğun tedavi ve takip, klinik pratikte hastalık şiddetini kontrol altına almada faydalı olabilir.
Anahtar Kelimeler: Demografik özellikler; pediatrik psöriyazis; klinik özellikler; hastalık şiddeti
ABSTRACT
Objective: The aim of this study is to evaluate sociodemographic and clinical characteristics in children with psoriasis (PsO) and to determine the relationship between these characteristics and disease severity. Material and Methods: This is a retrospective cross-sectional study. Thirty patients with PsO under the age of 18 who were admitted to the dermatology outpatient clinic between July 01, 2022 and June 30, 2023 were included in this study. The severity of the disease was evaluated using the Psoriasis Area Severity Index (PASI), and its relationship with other characteristics was analysed. Results: Of the patients, 53.3% (n=16) were male and 46.7% (n=14) were female, with an average age of 12.10±5.22 years. Stress was identified in 23.3% (n=7) of cases, infection in 13.3% (n=4), trauma in 13.3% (n=4), a family history in 46.7% (n=14), and medication use in 6.7% (n=2). It was found that 43.3% (n=13) of the patients had plaque, 26.7% (n=8) had guttate, 16.7% (n=5) had erythrodermic, 10% (n=3) had inverse, and 3.3% (n=1) had generalized pustular PsO. The PASI score ranged from a minimum of 2.3 to a maximum of 32.3, with an average score of 13.60±7.91. The severity of PsO was high in 70% of the cases, mild in 20%, and moderate in 10%. The PASI score was significantly higher in females (p=0.008) and in those with risk factors (p<0.001) compared to males and those without risk factors. Among the risk factors, the PASI score was higher in those who had infections (p=0.024) and those with a family history (p<0.001). According to multiple linear regression analysis, female gender (p=0.005) and the presence of a positive family history (p=0.033) were independently associated with an increase in PASI score. Conclusion: Disease severity tends to be higher in pediatric PsO patients with female gender and positive family history. In cases with these characteristics, more intensive treatment and close follow-up may be beneficial in terms of controlling the disease in clinical practice.
Keywords: Demographic characteristics; pediatric psoriasis; clinical characteristics; disease severity
Objective: The aim of this study is to evaluate sociodemographic and clinical characteristics in children with psoriasis (PsO) and to determine the relationship between these characteristics and disease severity. Material and Methods: This is a retrospective cross-sectional study. Thirty patients with PsO under the age of 18 who were admitted to the dermatology outpatient clinic between July 01, 2022 and June 30, 2023 were included in this study. The severity of the disease was evaluated using the Psoriasis Area Severity Index (PASI), and its relationship with other characteristics was analysed. Results: Of the patients, 53.3% (n=16) were male and 46.7% (n=14) were female, with an average age of 12.10±5.22 years. Stress was identified in 23.3% (n=7) of cases, infection in 13.3% (n=4), trauma in 13.3% (n=4), a family history in 46.7% (n=14), and medication use in 6.7% (n=2). It was found that 43.3% (n=13) of the patients had plaque, 26.7% (n=8) had guttate, 16.7% (n=5) had erythrodermic, 10% (n=3) had inverse, and 3.3% (n=1) had generalized pustular PsO. The PASI score ranged from a minimum of 2.3 to a maximum of 32.3, with an average score of 13.60±7.91. The severity of PsO was high in 70% of the cases, mild in 20%, and moderate in 10%. The PASI score was significantly higher in females (p=0.008) and in those with risk factors (p<0.001) compared to males and those without risk factors. Among the risk factors, the PASI score was higher in those who had infections (p=0.024) and those with a family history (p<0.001). According to multiple linear regression analysis, female gender (p=0.005) and the presence of a positive family history (p=0.033) were independently associated with an increase in PASI score. Conclusion: Disease severity tends to be higher in pediatric PsO patients with female gender and positive family history. In cases with these characteristics, more intensive treatment and close follow-up may be beneficial in terms of controlling the disease in clinical practice.
Keywords: Demographic characteristics; pediatric psoriasis; clinical characteristics; disease severity
REFERANSLAR:
- Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-85. [Crossref] [PubMed]
- Lewis-Beck C, Abouzaid S, Xie L, Baser O, Kim E. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence. 2013;7:199-205. [Crossref] [PubMed] [PMC]
- Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082. [Crossref] [PubMed]
- Eichenfield LF, Paller AS, Tom WL, Sugarman J, Hebert AA, Friedlander SF, et al. Pediatric psoriasis: evolving perspectives. Pediatr Dermatol. 2018;35(2):170-81. [Crossref] [PubMed]
- Bronckers IM, Paller AS, van Geel MJ, van de Kerkhof PC, Seyger MM. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Paediatr Drugs. 2015;17(5):373-84. [Crossref] [PubMed] [PMC]
- Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633-6. [Crossref] [PubMed]
- Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161-201. Erratum in: J Am Acad Dermatol. 2020;82(3):574. [Crossref] [PubMed]
- Warren RB, Kleyn CE, Gulliver WP. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol. 2011;164 Suppl 1:1-14. [Crossref] [PubMed]
- Mahé E, Maccari F, Beauchet A, Lahfa M, Barthelemy H, Reguiaï Z, et al; GEM Resopso. Childhood-onset psoriasis: association with future cardiovascular and metabolic comorbidities. Br J Dermatol. 2013;169(4):889-95. [Crossref] [PubMed]
- Mattei PL, Corey KC, Kimball AB. Cumulative life course impairment: evidence for psoriasis. Curr Probl Dermatol. 2013;44:82-90. [Crossref] [PubMed]
- Ros S, Puig L, Carrascosa JM. Cumulative life course impairment: the imprint of psoriasis on the patient's life. Actas Dermosifiliogr. 2014;105(2):128-34. English, Spanish. [Crossref] [PubMed]
- Matteo Megna and Maddalena Napolitano; Balato A, Scalvenzi M, Cirillo T, Gallo L, Ayala F, Balato N. Psoriasis in Children: A Review. Curr Pediatr Rev. 2015;11(1):10-26. [Crossref] [PubMed]
- Bruins FM, Bronckers IMGJ, Cai R, Groenewoud JMM, Krol M, de Jong EMGJ, et al. Treatment persistence in paediatric and adolescent patients with psoriasis followed into young adulthood. From topical to systemic treatment: a prospective, longitudinal, observational cohort study of 448 patients. Br J Dermatol. 2021;184(3):464-72. [Crossref] [PubMed] [PMC]
- Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk Factors for the Development of Psoriasis. Int J Mol Sci. 2019;20(18):4347. [Crossref] [PubMed] [PMC]
- Imafuku S, Zheng M, Tada Y, Zhang X, Theng C, Thevarajah S, et al. Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy. J Dermatol. 2018;45(7):805-11. [Crossref] [PubMed] [PMC]
- Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, et al; (Chair of Guideline Group). British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161(5):987-1019. [Crossref] [PubMed]
- Manchanda Y, De A, Das S, Chakraborty D. Disease Assessment in Psoriasis. Indian J Dermatol. 2023;68(3):278-81. [Crossref] [PubMed] [PMC]
- Pietrzak A, Grywalska E, Walankiewicz M, Lotti T, Roliński J, Myśliński W, et al. Psoriasis and metabolic syndrome in children: current data. Clin Exp Dermatol. 2017;42(2):131-6. [Crossref] [PubMed]
- Becker L, Tom WL, Eshagh K, Benjamin LT, Paller AS. Excess adiposity preceding pediatric psoriasis. JAMA Dermatol. 2014;150(5):573-4. [Crossref] [PubMed] [PMC]
- Jensen P, Zachariae C, Christensen R, Geiker NR, Schaadt BK, Stender S, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol. 2013;149(7):795-801. Erratum in: JAMA Dermatol. 2013;149(8):997. [Crossref] [PubMed]
- Burden-Teh E, Thomas KS, Ratib S, Grindlay D, Adaji E, Murphy R. The epidemiology of childhood psoriasis: a scoping review. Br J Dermatol. 2016;174(6):1242-57. [Crossref] [PubMed]
- Lysell J, Tessma M, Nikamo P, Wahlgren CF, Ståhle M. Clinical characterisation at onset of childhood psoriasis - a cross sectional study in Sweden. Acta Derm Venereol. 2015;95(4):457-61. [Crossref] [PubMed]
- Popadic S, Nikolic M. Pustular psoriasis in childhood and adolescence: a 20-year single-center experience. Pediatr Dermatol. 2014;31(5):575-9. [Crossref] [PubMed]
- Leow YH, Giam YC. Childhood psoriasis. J Sing Pediatr Soc. 1994;36:62-7.
- Kwon HH, Na SJ, Jo SJ, Youn JI. Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic. J Dermatol. 2012;39(3):260-4. [Crossref] [PubMed]
- Nieto Benito LM, Carretero G, Rivera-Díaz R, Carrascosa JM, Daudén E, de la Cueva P, et al; el grupo de estudio BIOBADADERM. Moderate to severe psoriasis in pediatric and young patients: The BIOBADADERM registry experience. Actas Dermosifiliogr. 2022;113(4):401-6. English, Spanish. [Crossref] [PubMed]
- Kamiya K, Oiso N, Kawada A, Ohtsuki M. Epidemiological survey of the psoriasis patients in the Japanese Society for Psoriasis Research from 2013 to 2018. J Dermatol. 2021;48(6):864-75. [Crossref] [PubMed] [PMC]
- Mercy K, Kwasny M, Cordoro KM, Menter A, Tom WL, Korman N, et al. Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States. Pediatr Dermatol. 2013;30(4):424-8. [Crossref] [PubMed] [PMC]
- Varni JW, Globe DR, Gandra SR, Harrison DJ, Hooper M, Baumgartner S. Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases. Eur J Pediatr. 2012;171(3):485-92. [Crossref] [PubMed]
- Stefanaki C, Lagogianni E, Kontochristopoulos G, Verra P, Barkas G, Katsambas A, et al. Psoriasis in children: a retrospective analysis. J Eur Acad Dermatol Venereol. 2011;25(4):417-21. [Crossref] [PubMed]
- Ozden MG, Tekin NS, Gürer MA, Akdemir D, Doğramacı C, Utaş S, et al. Environmental risk factors in pediatric psoriasis: a multicenter case-control study. Pediatr Dermatol. 2011;28(3):306-12. [Crossref] [PubMed]
- Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141(12):1527-34. [Crossref] [PubMed]
- Kumar B, Jain R, Sandhu K, Kaur I, Handa S. Epidemiology of childhood psoriasis: a study of 419 patients from northern India. Int J Dermatol. 2004;43(9):654-8. [Crossref] [PubMed]
.: İşlem Listesi